BOEHRINGER-INGELHEIM
14.9.2023 10:11:25 CEST | Business Wire | Press release
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative (SBTi). This validation underlines the company’s commitment to aligning its efforts to tackle climate change and reduce global warming in line with the 2015 Paris Agreement. The SBTi drives ambitious climate action in the private sector, by enabling organizations to set science-based emissions reduction targets, while maximizing transparency, accountability, and corporate leadership through annual disclosure and progress against the targets.
“Driving environmental stewardship to decarbonize our business operations, both within and beyond the factory gates, has been a long-time priority at Boehringer Ingelheim,” said Felix Gutsche, Boehringer Ingelheim’s Head of Corporate Strategy & Consulting. “Having our emissions reduction targets approved by a respected organization like SBTi confirms that our efforts align with the current global agenda.”
In 2021 Boehringer Ingelheim committed reducing absolute scope 1 and 2 GHG emissions1 by 58.9 percent and absolute scope 3 GHG emissions2 by 27.5 percent (from a 2019 base year). The recent SBTi verification underscores Boehringer Ingelheim’s ongoing efforts.
The company recently added its production sites Fornovo (Italy) and Paulínia (Brazil) to its list of carbon-neutral certified sites, bringing the total to seven worldwide. This achievement resulted amongst others from the purchase and installation of renewable energy solutions, as well as ambitious carbon reduction measures. At other sites, including Dortmund and Katharinenhof (Germany), Gainesville (USA), Sant Cugat (Spain), and Zhangjian (China) the company initiated the integration of circular economy principles into development and manufacturing processes, green mobility concepts, as well as sustainability building standards, e.g., Leadership in Energy and Environmental Design (LEED) certification for office buildings.
Boehringer Ingelheim’s efforts to implement its low-carbon transformation are driven through the MORE GREEN pillar within its Sustainable Development - For Generations program. To foster low-carbon technologies and solutions, Boehringer Ingelheim applies an internal carbon price of EUR 100 per ton CO2 emissions for investments, which has been fully established at all sites. The company also emphasizes environmental sustainability in larger projects, providing another EUR 130 million for projects that contribute to the global MORE GREEN goals. This fund has now initiated over 60 new environmental sustainability projects since 2020.
To support certified climate contribution projects that help mitigate the environmental impact of currently unavoidable emissions, Boehringer Ingelheim continues to partner with ClimateSeed. This reputable social enterprise offers a broad portfolio of internationally recognized Verified Emissions Reduction projects that not only safeguard biodiversity and ecosystem services, but also benefit local communities.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-green/boehringer-receives-sbti-validation-co2-reduction
References:
1Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy.
2Scope 3 GHG emissions are emissions from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution and use of sold products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914610507/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 15:13:00 CET | Press release
Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-fa
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 15:00:00 CET | Press release
Platform Supporting 1,500+ Game Developers Across 200+ Geographies to Host Networking Dinner and Co-Moderate Strategic Roundtable at Premier European Gaming Executive Summit Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios acro
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 15:00:00 CET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
